← Eichor
Study identifier: NCT03862677 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Determining Prognostic Immune Markers in Patients With Ovarian Cancer

Condition: Epithelial Ovarian Cancer  ·  Sponsor: Leiden University Medical Center

PhaseN/A
Planned participants300
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).

This description comes directly from the study's public registry record.

Talk to the study team

Judith R Kroep, MD PhD  ·  +31715263464  ·  j.r.kroep@lumc.nl

A F de Groot, MD  ·  +31715299126  ·  a.f.de_groot@lumc.nl

Always discuss trial participation with your own doctor first.

Locations (1)

Leiden University Medical CenterLeiden, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03862677